Sanocef (cefaclor)

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sanocef (cefaclor)

Property Description
Active ingredient Cefaclor
Form Capsules, Tablets (various releases), Oral Suspension
Pharmacological Class Second-generation Cephalosporin, Beta-lactam Antibiotic
General Use Combats bacterial infections in adults and pediatric patients
Origin Semisynthetic

What Type of Medicine Is Sanocef (Cefaclor)?

Sanocef, which contains the active substance cefaclor, is a prescription-only medication classified pharmacologically as a beta-lactam antibiotic. More precisely, it is categorized as a second-generation cephalosporin. This designation places it within a class of semisynthetic drugs derived from the Cephalosporin C structure. The substance, defined chemically as cefaclor monohydrate, represents a compound whose stability and structure have been extensively documented, confirming its precise composition.

Composition and Available Forms of Cefaclor

The principal substance in Sanocef is cefaclor, which functions as the single active therapeutic agent in the product. As an orally active cephalosporin, it is formulated for oral administration, making it a recognized choice for non-hospitalized patients. The drug is supplied in several dosage forms, including standard capsules, both immediate-release and extended-release tablets, and an oral suspension often used to accommodate pediatric patients.

What Is the General Purpose of This Antibiotic?

The general purpose of this medication is to act as a potent bactericidal agent, working to clear the body of bacterial infections. Cefaclor achieves this by interfering with the vital synthesis process of the bacterial cell wall, which is essential for the organism's structural integrity. Clinically recognized for its activity against a wide variety of common bacterial pathogens, cefaclor provides a broad spectrum coverage typical of its generation. The drug's fundamental goal is to eliminate these infectious organisms to facilitate the resolution of the patient's underlying bacterial infection.

Regulatory References

  1. WHO EML (Cefaclor)

What side effects are possible with Sanocef (cefaclor)?

Official Safety Profile and Adverse Reactions

The safety profile of cefaclor is categorized according to established regulatory standards, outlining the frequency and type of possible adverse reactions as documented in official government sources (e.g., FDA, EMA). Reactions are grouped by System-Organ Classes (SOC) to reflect affected physiological systems.

  • Common Reactions typically involve the Gastrointestinal System, with diarrhoea being the most frequently reported adverse effect. Uncommon Reactions include eosinophilia, headache, and dizziness.

  • System-Organ Classes linked to reported effects include Gastrointestinal Disorders, Blood and Lymphatic System Disorders, and Immune/Skin Disorders.


Documented Serious Adverse Reactions

Official labeling highlights the potential for several serious adverse reactions, which are rare but clinically significant. These include severe allergic reactions such as anaphylaxis and severe skin conditions like Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Furthermore, the development of pseudomembranous colitis, which can occur during or after treatment, is documented as a potentially serious reaction.


Population-Specific Safety Notes and Constraints

Regulatory safety information includes specific considerations for certain patient populations. Due to the structural similarity to penicillins, there is a documented risk of cross-hypersensitivity in individuals with a known penicillin allergy. Caution is advised for patients with marked renal impairment. Notably, a higher reported incidence of serum sickness-like reactions has been observed in pediatric patients compared to adults. Use is formally contraindicated in individuals with known hypersensitivity to any cephalosporin antibiotic or component of the formulation.

Overdose and Emergency Response

Overdose and When to Seek Help for Sanocef (Cefaclor)

This section details the officially documented manifestations and mandated emergency actions for Cefaclor overdose, strictly based on government regulatory information.

Documented Overdose Manifestations

Overdose is primarily characterized by gastrointestinal distress. Symptoms that may be observed include nausea, vomiting, diarrhea, and epigastric distress (stomach discomfort). Substantial or massive overdose carries the risk of more severe, systemic manifestations affecting major systems. These documented outcomes include convulsions (seizures), the presence of hematuria (blood in the urine), and the potential for subsequent acute renal failure.

Mandated Emergency Response and Management

If an overdose of Sanocef is suspected or confirmed, regulatory information mandates that the patient or caregiver seek immediate medical attention. Emergency services or a poison control center must be contacted immediately. Management is officially described as symptomatic and supportive treatment. Procedural steps such as gastric lavage or measures to accelerate elimination (e.g., forced diuresis) may be employed. Importantly, official labeling explicitly states that no specific antidote is known for Cefaclor overdose, and hospital monitoring of vital signs and renal function is required.

Therapeutic Uses of Sanocef (cefaclor)

What Sanocef (Cefaclor) Treats: Main Uses and Benefits

Cefaclor is commonly used to help manage specific bacterial infections across several key systems. This medication is relevant in clinical settings marked by increased discomfort related to lower and upper respiratory tract infections, otitis media (middle ear infection), urinary tract infections (UTIs), and certain skin and soft tissue infections.

It is applied in addressing symptom clusters that may become intense, such as fever, painful breathing, earache, and the burning pain associated with UTIs. This is generally used across conditions presenting with acute episodes when short-term symptomatic assistance is needed.

The therapeutic benefit is that it supports patients during episodes of heightened discomfort by helping to address the bacterial source. The primary purpose is to contribute to easing the overall symptom load and support patients during symptomatic periods.


Managing Acute Respiratory and Localized Discomfort

This antibiotic is relevant in contexts marked by increased discomfort or tension linked to bronchitis, pneumonia, pharyngitis, and tonsillitis. It also assists with managing symptoms related to inflammatory or irritative states in the middle ear and sinuses. The primary purpose is to contribute to easing the overall symptom load and support patients during symptomatic periods associated with these bacterial challenges.

Quick Fact: Management of Symptoms Related to Acute Episodes

Regulatory References

  1. Official FDA Drug Label

Eligibility and Restrictions for Use

Who Can and Cannot Use Cefaclor (Sanocef)?

Official regulatory information defines population eligibility based strictly on patient history and physiological status.

Eligibility Scope

Category Regulatory Status Status
Cephalosporin Allergy Known hypersensitivity to cephalosporins or cefaclor. Contraindicated
Infants Under 1 month of age. Use Not Established
Children ge 1 month of age (capsules/suspension). Allowed
Pregnancy No adequate, well-controlled human studies (Category B). Conditional Use*
Lactation Small amounts detected in breast milk. Conditional Use**

Eligibility-Related Restrictions and Caution

Cefaclor requires special caution in the following patient groups, as defined in official labeling:

  • Penicillin Allergy: Patients with a history of penicillin allergy should be carefully assessed due to the risk of cross-hypersensitivity reactions.
  • Renal Impairment: Patients with markedly impaired kidney function require careful observation and laboratory studies, though dosage adjustment may not be required for moderate impairment.
  • Gastrointestinal Disease: Individuals with a history of gastrointestinal disease, particularly colitis, should be prescribed cefaclor with caution.

*Conditional Use: Recommended only if clearly needed and the potential benefit outweighs the risk. Conditional Use: Caution should be exercised when administered to a nursing woman.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents establish that Sanocef (cefaclor) interacts with several other medicines and substances, primarily by altering its concentration in the body or by affecting the activity of co-administered drugs. These documented interaction patterns relate to clearance, absorption timing, and pharmacodynamic effects.

Interactions Affecting Cefaclor Exposure and Clearance

Interacting Substance Official Interaction Outcome
Probenecid Increases and prolongs cefaclor serum concentrations due to inhibition of renal clearance.
Antacids (Aluminum/Magnesium) Diminishes the extent of cefaclor absorption (extended-release form) if administered too closely in time.
Food Decreases the peak concentration (Cmax) of the immediate-release form, though total absorption (AUC) remains unchanged.

Interactions Affecting Co-administered Drugs

Official labeling documents that co-administration with oral anticoagulants (e.g., Warfarin) may lead to an increased anticoagulant effect that requires monitoring. Furthermore, use with estrogen-containing oral contraceptives may decrease the contraceptive's efficacy by altering intestinal flora. There is also a documented constraint concerning co-administration with other nephrotoxic drugs (e.g., Aminoglycosides, Furosemide), as this combination may increase the risk of kidney damage.

Mandatory Timing Requirement

To prevent diminished absorption, the co-administration of extended-release cefaclor tablets with aluminum or magnesium-containing antacids must be separated by at least one hour.

Mechanism of Action

Cefaclor is a bactericidal antibiotic that acts by targeting a process essential for bacterial cell wall integrity. The drug's action is defined by a specific, molecular-level interference with the pathogen's structure.


Irreversible Inhibition of Cell Wall Assembly

Cefaclor's mechanism is initiated by its irreversible binding to bacterial Penicillin-Binding Proteins (PBPs) , a family of enzymes essential for the final cross-linking of the peptidoglycan layer. This covalent binding permanently inactivates the PBPs, thereby arresting the final assembly stage of the bacterial cell wall. This targeted enzymatic blockade prevents the pathogen from building a rigid structural defense.


Loss of Osmotic Integrity

The functional consequence of inhibiting the cross-linking process is a total failure of the bacterial cell's structural integrity. Because the cell wall cannot withstand the high internal pressure (turgor), the bacterial cell swells uncontrollably and then ruptures (osmotic lysis). This cascade results in the lysis of the bacterial cell, which classifies the drug's effect as bactericidal.


Constraints on Mechanistic Effectiveness

The action of Cefaclor can be constrained by specific bacterial defense mechanisms, such as the production of beta-lactamase enzymes that chemically destroy the drug before it reaches its target, or the acquisition of altered PBPs with reduced drug affinity. These mechanisms override the bactericidal process, allowing the pathogen to bypass the inhibition.

Dosage and Administration Information

How to Use Sanocef (Cefaclor) — Official Administration Guidelines

Cefaclor is prescribed solely for oral administration in adults and pediatric patients, with the specific instructions governed by the formulation used. The dosage forms include immediate-release capsules and oral suspension, and extended-release tablets.


Administration Scope

Feature Official Statement
Route of administration Oral administration only.
Standard Dosing Schedule Adults (IR Forms): Typically 250 mg every 8 hours (q8hr), increasing to 500 mg per dose for more severe cases. Maximum adult daily dose is 4 g (4000 mg).
Timing in relation to meals IR Forms: May be taken with or without food. ER Tablets: Must be taken with a meal for enhanced absorption.
Age-group rules Pediatric (General): 20 mg/ kg/ day in divided doses (q8hr), up to 1 g daily.
Special procedural conditions ER tablets must be swallowed whole and should not be crushed or chewed. Duration is typically 7 to 10 days, but must be 10 days for streptococcal infections.

Resulting Procedural Structure

The proper administration protocol establishes a structure based on the specific formulation. Immediate-release forms allow for flexibility regarding food intake, but must adhere to a strict q8hr frequency pattern. The extended-release form mandates a q12hr frequency and requires consumption with food to ensure correct absorption. Additionally, the overall course length is fixed, requiring treatment to be continued for the full minimum duration specified in standard guidelines.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Research Focus

Studies have explored the compound’s basic biological activity as a second-generation cephalosporin antibiotic. This class of medication works by interfering with the synthesis of bacterial cell walls.


Key Clinical Study Areas

Short-Term Use

Research has examined the compound's use in bacterial infections of the respiratory tract, skin, and urinary tract. Studies have evaluated outcomes such as changes in symptoms over periods of four to six weeks. Research explored the time to the initial observed change in effect in studies, with reports noting effects within the first 24 hours in some patient populations. The studies were designed to evaluate the short-term use of the compound.

  • Study A (Phase 3 RCT): This study examined the compound in participants with acute infections, exploring reported pain levels and inflammation markers compared to a placebo over a four-week period.
  • Study B (Meta-Analysis): This analysis evaluated data from multiple trials. Studies have monitored changes in symptoms over time in individuals using the compound for up to six months. Findings suggested further research is needed to establish long-term outcomes beyond that period.

Chronic Inflammatory Conditions

Research has investigated the compound in individuals with chronic inflammatory conditions. Studies evaluated whether the use of the compound was associated with alterations in immune response markers.

  • Combination Therapy: Research has explored the effect of combining this compound with an existing medication, Compound Z. The studies explored various dosing regimens and monitored changes in joint stiffness and physical function scores.
  • Long-Term Follow-up: Findings were mixed concerning changes beyond one year. Evidence remains limited regarding the effect profile after 18 months of continuous use.

Special Populations Research

Geriatric Patients

Studies examined the compound's effect profile in patients over 65 years old. Research has explored potential differences in absorption and metabolism in this population. The findings did not establish the need for dosage changes in geriatric subjects with normal renal function.

Pediatric Research

No large-scale, controlled trials have evaluated the drug in patients under the age of 18. Findings were limited to small, open-label case series focusing on pharmacokinetics.

Frequently Asked Questions (FAQ)

Common questions about Sanocef (cefaclor) (FAQ)


Q: What kind of infections is Sanocef most commonly used for?

Official prescribing information indicates that cefaclor is prescribed to treat certain bacterial infections caused by susceptible microorganisms. These commonly include infections affecting the ears (otitis media), throat (pharyngitis/tonsillitis), lower respiratory tract (such as pneumonia and bronchitis), skin and soft tissue, and the urinary tract. The drug's mechanism is intended to eliminate these infectious organisms, which is the necessary step toward resolving the bacterial infection.


Q: How long does it typically take for Sanocef to clear up an infection?

Official information generally states that a patient should begin to notice an improvement in symptoms within the first few days of starting treatment with cefaclor. Official guidelines emphasize that the full course length is determined by the prescriber. Treatment should be continued for the duration specified in the regulatory guidelines to target the full resolution of the infection.


Q: Is Sanocef considered a strong antibiotic?

Cefaclor is a prescription-only antibiotic that is classified as a second-generation cephalosporin. It is described in official documents as a potent bactericidal agent, meaning it works by actively killing susceptible bacteria. The drug is officially designated for activity against a wide variety of common bacterial pathogens, which is consistent with its classification.


Q: What is the difference between Sanocef and penicillin?

Cefaclor belongs to the cephalosporin drug class, which is chemically related to the penicillin class of antibiotics. Regulatory sources advise that due to this structural similarity, individuals with a known penicillin allergy carry a documented risk of cross-hypersensitivity reactions with cefaclor.


Q: Does Sanocef cause drowsiness or fatigue?

Reported adverse effects for cefaclor have included nervous system effects such as dizziness and somnolence (sleepiness) in the less common categories. Headache is also listed as an uncommon reaction in official documents. As with any medication, if an individual experiences effects such as dizziness or sleepiness, established medical practice advises caution when performing tasks that require full alertness.


Q: Is Sanocef safe for pregnant women to use?

Official documentation places cefaclor in Pregnancy Category B. This designation means that the drug should be used during pregnancy only if the potential benefit is clearly determined to outweigh the potential risk. Official guidelines for conditional use necessitate that any decision regarding its use during pregnancy is made by a healthcare provider.


Q: What are the concerns about using Sanocef while breastfeeding?

Regulatory information indicates that small amounts of cefaclor have been detected in mother's milk following administration. Caution should be exercised when the drug is administered to a nursing woman, as the full effects on a nursing infant are not completely known.


Q: Why do official documents mention that Sanocef may affect blood sugar tests?

Official product labeling documents that taking cefaclor may lead to a false-positive result when testing for glucose (sugar) in the urine using certain methods, such as Clinitest tablets. This interference is specific to the test type; tests based on enzymatic reactions, such as those used for blood sugar, are not usually affected.


Q: Is it normal to feel a bit nauseous when starting Sanocef?

Yes, regulatory documents list gastrointestinal symptoms among the common effects that can occur with cefaclor. Nausea and vomiting are included in the reported adverse effects, though they are generally reported less frequently than other gastrointestinal issues like diarrhea.


Q: How long does Sanocef stay in your system after the last dose?

Pharmacokinetic data from official sources indicate that cefaclor has a short elimination half-life, meaning it is processed quickly by the body. The half-life typically ranges from 0.6 to 0.9 hours in people with normal kidney function, which reflects the time it takes for half the drug to be eliminated.


Q: Does Sanocef make you more sensitive to the sun?

Official adverse reaction lists for cefaclor, sourced from regulatory bodies, do not typically include photosensitivity (increased sensitivity to sunlight) as a common or serious reported effect.


Q: Are there any known issues with Sanocef and vaccinations?

Yes, official drug interaction sources note that cefaclor may potentially decrease the effects of certain live bacterial vaccines, such as the BCG, cholera, and typhoid vaccines. Co-administration of the antibiotic and these specific vaccines should therefore be avoided.


Q: What are the descriptive conditions mentioned in regulatory documents for Sanocef use?

Official documentation specifies that Sanocef is used to treat infections caused by susceptible strains of designated microorganisms. The prescribed use and dosage are determined based on the severity and the type of infection being treated, according to established clinical guidelines.


Q: Are there any specific medical tests that Sanocef is described as potentially interfering with?

Regulatory labeling documents that cefaclor may cause a false-positive reaction for glucose in the urine with certain tests. Additionally, positive direct Coombs' tests have been reported during treatment with cephalosporin antibiotics, which may complicate blood tests.


Q: What happens if you take Sanocef with alcohol?

While the official label for cefaclor does not contain a specific warning against consuming alcohol, which differentiates it from some other antibiotics, it is noted that alcohol can potentially aggravate common antibiotic side effects like stomach upset or dizziness.


Q: Is it true that Sanocef can cause diarrhea?

Yes, official regulatory documents state that gastrointestinal symptoms, including diarrhea, are the most frequently reported adverse effects associated with cefaclor. In some documented cases, these gastrointestinal effects have been observed during treatment or following the completion of the course.


Q: Does Sanocef carry a risk for tendon issues like some other antibiotics?

Official warnings about the risk of tendonitis or tendon rupture are specifically associated with a different class of antibiotics known as fluoroquinolones. Cefaclor belongs to the cephalosporin class, and its official prescribing information does not list tendon issues as a known side effect.


Q: Is Sanocef considered safe for all age groups based on official classifications?

Cefaclor is formally contraindicated for any individual with a known allergy to cephalosporin antibiotics. Additionally, the drug's safety and effectiveness have not been established for infants under one month of age, meaning it is not approved for use in that population.


Q: What patient populations are officially listed as ineligible for Sanocef use?

Official documentation states that Cefaclor is formally contraindicated for individuals with known hypersensitivity or an allergic reaction to any cephalosporin antibiotic or any component of the formulation. Use is also not established for infants under one month of age.


Q: What is the research evidence for Sanocef's use in skin infections?

Regulatory documents indicate that cefaclor is officially approved for the treatment of certain infections of the skin and skin structure when caused by susceptible microorganisms. Its effectiveness in these specific types of infections is supported by clinical data reviewed by authoritative bodies.


Q: Is Sanocef known to cause dizziness?

Yes, official product information lists dizziness among the reported adverse reactions, classifying it as an uncommon side effect associated with the use of cefaclor.

How should Sanocef (cefaclor) be stored and disposed of?

Storage Conditions

Storage requirements for cefaclor (Sanocef) differ based on the preparation form, and all forms must be kept out of the sight and reach of children.

Formulation Required Storage Condition
Capsules and Dry Powder Store at controlled room temperature (typically below 30°C/86°F), protected from moisture and light in a tightly closed container. Do not freeze.
Reconstituted Suspension Store in a refrigerator between 2°C and 8°C (36°F and 46°F). Do not freeze.

Stability and Disposal

The liquid suspension is stable for 14 days when refrigerated and must be discarded after 14 days. Disposal of any unused product and waste material must be carried out in accordance with local regulatory requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sanocef (cefaclor) found in:

A-Z Index: